Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at the Mcm5 protein test to diagnose cancer of the bile duct, gallbladder or pancreas (TRANSBIL)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new test called the Mcm5 protein test to see if it can help diagnose cancer of the bile duct, gallbladder or pancreas.
More about this trial
Doctors use blood tests, scans and
But it is not always easy to be sure of the diagnosis based on these results. Doctors hope a test that looks for a protein called Mcm5 will be better at diagnosing these cancers. Mcm stands for ‘minichromosome maintenance’ protein. This is a new test. Research so far suggests it is very accurate. But we need to make sure it is reliable before it can be widely used to diagnose cancer.
In this trial, patients will have the Mcm5 test as well as the usual tests, not instead of them. If you take part, the results of the Mcm5 test will not affect your treatment or care. But if the trial proves the Mcm5 test is good enough, it may benefit other patients in the future.
The aim of this trial is to find out if testing for the Mcm5 protein can help diagnose cancer of the bile duct, gall bladder or pancreas.
Who can enter
You can enter this trial if you are at least 18 years old and;
- Have cancer of the bile duct, gallbladder or pancreas or
- Are having tests to find out if you have cancer of the bile duct, gallbladder or pancreas or
- Have a benign (non cancerous) condition of the bile duct, gallbladder or pancreas, such as
pancreatitis, sclerosing cholangitis or jaundicecaused by stones in the bile duct
This trial will recruit more than 200 people into two groups.
Group 1 will be those with suspected cancer, or those who have already been diagnosed with cancer.
Group 2 will be those with a non cancerous condition (see eligibility criteria above). They are the ‘control group’, and they have the same tests as group 1. This is to make sure the Mcm5 test is positive for cancer, but negative for other conditions.
After these tests, the doctors will take a biopsy. To do this they will either pass a tube down through your mouth and throat, through your stomach and into your gall bladder or pancreas (an ERCP). Or they will use a needle through your skin.
If you have an ERCP, the doctors will also take a small sample of fluid called
The staff in the lab will test these samples in the usual way. But they will also test them for the Mcm5 protein.
You will not have any additional tests for this trial. But the doctors will take some extra samples when you have a biopsy. You should not have to stay in hospital as a result of taking part in this trial.
How to join a clinical trial
Dr Steve Pereira
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
University College London (UCL)